Recombinant vaccinia virus for expressing CRISPR / Cas9 gene editing system and application

By constructing the recombinant vaccinia virus vector plasmid pCB-Cas9-dmCZ and using the characteristics of vaccinia virus, the problem of low delivery and expression efficiency of CRISPR/Cas9 gene editing system was solved, and efficient gene editing effect was achieved, and screening of marker genes by selecting marker genes Ensure purification and function of the recombinant virus.

CN118909980APending Publication Date: 2024-11-08HANGZHOU NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411005677.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the delivery and expression efficiency of the CRISPR/Cas9 gene editing system is inefficient, especially in large-scale sample processing and in vivo delivery, and viral vector delivery is prone to trigger immune responses and off-target effects.

Method used

Recombinant vaccinia virus as a vector, recombinant vaccinia virus vector plasmid was constructed by inserting CRISPR/Cas9 elements into the TK gene region of vaccinia virus, and early/late promoter of vaccinia virus to drive Cas9 gene expression and modified H5 promoter to drive gRNA expression. pCB-Cas9-dmCZ constructs recombinant vaccinia virus through intracellular homologous recombination mechanisms, achieving effective delivery and expression of the CRISPR/Cas9 gene editing system.

Benefits of technology

The efficient expression of CRISPR/Cas9-related elements was achieved, which significantly weakened the mCherry red fluorescent protein marker gene in target cells, demonstrated the gene editing effect, and ensured the purification and function of the recombinant virus through selection marker gene screening and verification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909980A_ABST
    Figure CN118909980A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant vaccinia virus for expressing a CRISPR / Cas9 gene editing system and application of the recombinant vaccinia virus. A TK gene region of the recombinant vaccinia virus comprises an expression cassette of a CRISPR / Cas9 element, in a marker gene shearing cell model, the VV-Cas9-dmCZ recombinant vaccinia virus can be delivered and express a CRISPR / Cas9 system through virus infection target cells, and an integrated or transfected mCherry red fluorescent protein marker gene is effectively sheared, so that the recombinant vaccinia virus can be used for preparing the recombinant vaccinia virus. And intracellular gene editing based on vaccinia virus vector delivery is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a recombinant vaccinia virus for delivering and expressing a CRISPR / Cas9 gene editing system in target cells and applications thereof. Background Art

[0002] Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a special DNA sequence found in bacteria, which is related to the natural immune defense of bacteria. In recent years, based on the CRISPR principle, related elements and proteases have been genetically engineered to create convenient and powerful gene editing tools. The most widely used of these is the CRISPR / Cas9 system, which provides a disruptive tool for modifying large genomic sequences, which was previously extremely difficult to operate.

[0003] In order for the CRISPR / Cas9 system to play a gene editing role, the relevant elements of the CRISPR / Cas9 system, the Cas9 protease gene and gRNA (i.e., guide RNA, which determines the target sequence to be cut through base complementarity) must first be specifically delivered into the target cells and expressed. The delivery method and its efficiency become the key and "bottleneck" that restricts the efficiency and even the success of gene editing.

[0004] There are two ways to deliver the CRISPR / Cas9 system: non-viral vectors and viral vectors. The former include liposome transfection, electroporation and microinjection, while the latter have so far used adeno-associated virus (AAV) vectors, adenovirus (AdV) vectors, lentivirus (LV) vectors and bacteriophages.

[0005] Generally speaking, among non-viral vector delivery methods, liposome transfection is simple to operate, but the delivery efficiency is relatively low and the variation is large, while electroporation and microinjection are accurate and efficient, but they involve expensive instruments and require trained professionals to operate. All non-viral vector delivery methods are not suitable for large-scale sample processing and are often not suitable for in vivo delivery. Relatively speaking, viral vector delivery efficiency is very high and can be used for in vivo delivery, but the viral vector itself can stimulate the host's immune response, and viral vector delivery tends to over-express CRISPR / Cas9 for a long time, which can lead to enhanced off-target effects.

[0006] Each viral vector has its own advantages and disadvantages. For example, AAV vector is the most commonly used viral vector for delivering CRISPR / Cas9. It has high delivery efficiency and low risk of genome integration, but the capacity of AAV vector is too small (only 4.7kb), and usually two or even three AAV vectors are required to complete the delivery of the entire CRISPR / Cas9 system. AdV vector delivery efficiency is also very high, but it has strong immunogenicity. LV vector immunogenicity is very low, but it has the potential risk of integration into the host genome and causing cancer.

[0007] Vaccinia virus is one of the largest and most complex viruses discovered so far. It is a live vaccine virus for preventing smallpox. After years of large-scale vaccination of the population, vaccinia virus has been proven to have a good biosafety record. After smallpox was eradicated worldwide, vaccinia virus has been deeply studied and widely used as a genetic engineering expression vector. Based on the following characteristics of the virus, it has been increasingly widely used in the field of gene therapy:

[0008] 1. Safety: Vaccinia virus is the only DNA virus that can replicate in the cytoplasm. It will not integrate into the host cell genome and has no safety issues such as carcinogenicity.

[0009] 2. High expression efficiency: Vaccinia virus can be cultured to a very high titer (>10 9 pfu / ml), usually infected for 1-3 hours, without any drug resistance screening, more than 90% of infected cells can express the target gene product;

[0010] 3. Wide range of infected cells: can infect almost all types of mammalian cells;

[0011] 4. Can infect / transduce both dividing and non-dividing cells;

[0012] 5. Large genome capacity: at least 25kb of foreign genes can be inserted without affecting its genetic stability;

[0013] 6. Natural tumor targeting: After injection into the body, most vaccinia viruses will accumulate at the tumor site. Summary of the invention

[0014] The purpose of the present invention is to address the deficiencies of the prior art and provide a recombinant vaccinia virus for delivering and expressing the CRISPR / Cas9 gene editing system and its application.

[0015] In order to achieve the above object, the present invention is implemented by the following technical scheme: a recombinant vaccinia virus expressing CRISPR / Cas9 gene editing system, as a model to verify the feasibility of the principle of the present invention, the CRISPR / Cas9 element expression cassette of the mCherry red fluorescent protein marker gene is inserted into the vaccinia virus TK gene region, and the Cas9 gene expression is driven by the artificially synthesized vaccinia virus early / late promoter (P-se / l); the gRNA expression is driven by the H5 promoter (mH5) modified by the vaccinia virus. The recombinant vaccinia virus is based on the recombinant vaccinia virus expression plasmid pCB-Cas9-dmCZ transfected Vero cells, and then the wild-type vaccinia virus WR strain is used to infect Vero cells, and the intracellular homologous recombination mechanism is constructed.

[0016] Furthermore, the complete nucleic acid sequence of the recombinant vaccinia vector expression plasmid pCB-Cas9-dmCZ is shown in SEQ ID No. 1.

[0017] Furthermore, the parent virus of the recombinant vaccinia virus is the vaccinia virus WR strain.

[0018] Furthermore, the structure of the recombinant vaccinia expression plasmid pCB-Cas9-dmCZ includes the Cas9 gene and its upstream artificially synthesized vaccinia virus early / late promoter P-se / l, gRNA and its upstream vaccinia virus modified H5 promoter mH5, and a selectable marker gene expression cassette in series with the target gene expression cassette; the P-se / l drives the expression of the Cas9 gene, and the mH5 drives the expression of the gRNA; wherein the gRNA is an RNA that guides the cleavage of the mCherry red fluorescent protein marker gene, the selectable marker genes are the EGFP gene and the gpt resistance gene, and the target gene is the Cas9 gene and the gRNA.

[0019] Furthermore, the nucleic acid sequence of the Cas9 gene is shown as SEQ ID No.3, the nucleic acid sequence of P-se / l is shown as SEQ ID No.4, the nucleic acid sequence of the gRNA is shown as SEQ ID No.2, and the nucleic acid sequence of mH5 is shown as SEQ ID No.5.

[0020] Furthermore, the selectable marker genes include an enhanced green fluorescent protein (EGFP) gene and a gpt drug resistance gene.

[0021] Furthermore, the nucleic acid sequence of the selectable marker gene gpt drug resistance gene is shown as SEQ ID No.6; the nucleic acid sequence of the selectable marker gene EGFP is shown as SEQ ID No.7.

[0022] Furthermore, the EGFP gene is fused to the Cas9 gene via a 2A peptide, and the gpt drug resistance gene is driven for expression by a vaccinia virus P7.5 early / late promoter (P7.5).

[0023] Furthermore, the amino acid sequence of the protein encoded by the Cas9 gene is shown in SEQ ID No.8; the amino acid sequence of the protein encoded by the selectable marker gene EGFP is shown in SEQ ID No.9; and the amino acid sequence of the protein encoded by the selectable marker gene gpt drug resistance gene is shown in SEQ ID No.10.

[0024] The present invention also provides a use of any of the above-mentioned recombinant vaccinia viruses in targeted cell delivery and expression of the CRISPR / Cas9 system and gene editing of any endogenous or exogenous target gene in the target cell.

[0025] The term "gene editing" includes, but is not limited to: delivering and expressing CRISPR / Cas9 related elements to target cells such as tumors through recombinant vaccinia virus vectors, resulting in genetic changes such as splicing, inactivation, insertion or mutation of endogenous genes or exogenous genes (such as marker genes) in the target cells.

[0026] The beneficial effects of the present invention are as follows: the present invention first constructs a recombinant vaccinia virus vector plasmid pCB-Cas9-dmCZ, uses the plasmid to transfect, and then infects Vero cells with a wild-type vaccinia virus WR strain, produces a recombinant vaccinia virus through an intracellular homologous recombination mechanism, and then through the expression of a selectable marker gene EGFP in series with a target gene expression cassette, based on the green fluorescence phenotype produced by its expression product, and the expression of a drug resistance protein to produce a gpt resistance phenotype, the recombinant vaccinia virus can be conveniently screened. After the recombinant vaccinia virus VV-Cas9-dmCZ produced by the present invention infects cells, it can effectively express and produce gRNA and Cas9 protein. The above-mentioned recombinant vaccinia virus VV-Cas9-dmCZ can effectively express CRISPR / Cas9-related element Cas9 protein and gRNA sequence in a tumor cell model infected with stably expressed or transiently transfected mCherry red fluorescent protein, and cut the mCherry target gene sequence, resulting in a gene editing effect of reduced red fluorescence in the target cell. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The diagram shows the steps for constructing and cloning the recombinant vaccinia virus expression plasmid pCB-Cas9-dmCZ and the core component schematic diagram of the recombinant vaccinia virus VV-Cas9-dmCZ; wherein P-se / l is a synthetic vaccinia virus early / late promoter, gpt is a drug resistance marker gene, mH5 is a vaccinia virus modified H5 promoter, and P7.5 is a vaccinia virus P7.5 early / late promoter;

[0028] Figure 2 This is a schematic diagram of observation under a fluorescence microscope after transfection of the recombinant vaccinia virus vector plasmid pCB-Cas9-dmCZ and infection of Vero cells with the wild-type vaccinia virus WR strain;

[0029] Figure 3 is the map of the recombinant vaccinia virus expression plasmid pCB-Cas9-dmCZ;

[0030] Figure 4 is a schematic diagram of plaques of recombinant vaccinia virus;

[0031] Figure 5 It is a schematic diagram of Western Blot detection of Cas9 expression after infection of cells;

[0032] Figure 6 is a schematic diagram of the gRNA expressed by the recombinant vaccinia virus VV-Cas9-dmCZ;

[0033] Figure 7 This is a schematic diagram of fluorescence microscopy observation after the recombinant vaccinia virus VV-Cas9-dmCZ infected HeLa cells that had been transfected with LeGo-c-zeo plasmid (expressing mCherry), wherein PBS is a buffer control and VV-dcdk5 is a negative control virus;

[0034] Figure 8 This is a schematic diagram of flow cytometry detection after the recombinant vaccinia virus VV-Cas9-dmCZ infected HeLa cells that had been transfected with LeGo-c-zeo plasmid (expressing mCherry), where PBS is the buffer control and VV-dcdk5 is the negative control virus;

[0035] Fig. 9 Schematic diagram of flow cytometry detection after recombinant vaccinia virus VV-Cas9-dmCZ infected 786-O cells stably expressing the mCherry red fluorescent marker gene (A, B);

[0036] Fig.10 This is a schematic diagram of gel electrophoresis after T7E1 digestion. DETAILED DESCRIPTION

[0037] The recombinant vaccinia virus VV-Cas9-dmCZ of the present invention is composed of a vaccinia virus WR strain as a parent, a CRISPR / Cas9 element inserted into the TK gene region of the virus, an artificially synthesized vaccinia virus early / late promoter P-se / 1 for driving the expression of exogenous genes, and a selectable marker gene EGFP fused with the Cas9 gene for screening recombinant vaccinia viruses, wherein the expression product of the marker gene, green fluorescent protein, has a green fluorescent phenotype to facilitate the screening of recombinant vaccinia viruses. The expression of another screening marker gpt drug resistance is driven by the vaccinia virus P7.5 early / late promoter.

[0038] The present invention adopts the classical homologous recombination method to construct recombinant vaccinia virus. First, the recombinant vaccinia expression plasmid pCB-Cas9-dmCZ is constructed by overlapping PCR and molecular cloning, and then the plasmid pCB-Cas9-dmCZ is transfected, and then the wild-type vaccinia virus WR strain is infected with Vero cells, and the recombinant virus is screened out by the marker gene EGFP expression color development and gpt resistance plaque purification.

[0039] Example 1: Construction of recombinant vaccinia vector plasmid pCB-Cas9-dmCZ

[0040] (1) PCR primers

[0041] Order the following PCR primers from a commercial company:

[0042]

[0043] (2) The general PCR reaction is as follows

[0044] Kod polymerase Mix 25μL Upstream primer (10 μM) 2.5μL Downstream primer (10 μM) 2.5μL template 0.2μL <![CDATA[ddH2O]]> Add to 50 μL

[0045] (3) PCR reaction and cloning

[0046] The vaccinia vector mother plasmid pCB and the plasmid containing CRISPR / Cas9 related fragments preserved in this laboratory were used as templates, and the above primers were used for PCR. The experimental conditions were: pre-denaturation at 94°C for 2 minutes; denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds; extension at 72°C for 1 minute, repeated 30 cycles, and the PCR product was run on 1% agarose gel electrophoresis. The results were observed and recorded by gel imaging analyzer, and the target band was cut and recovered. The target gene fragment was recovered using a gel recovery kit. Then, the Gibson kit was used for connection, and the clone with the correct insertion direction was selected. The sequencing was verified to be correct, and the recombinant vaccinia vector plasmid pCB-Cas9-dmCZ was obtained. The plasmid map is shown in Figure 3 .

[0047] Example 2: Construction and screening of recombinant vaccinia virus VV-Cas9-dmCZ

[0048] Vero cells were inoculated into 6-well plates and grown to 80% of the cells the next day. Liposome transfection was performed according to the product instructions of Yisheng Biotechnology Shanghai Co., Ltd. 250 μL of serum-free 1640 medium was used to dilute 4 μg of pCB-Cas9-dmCZ plasmid in each well of cells, and 250 μL of serum-free 1640 medium was used to dilute 10 μL of Hieff TransTM liposome nucleic acid transfection reagent. The two were mixed and incubated at room temperature for 20 minutes. The cells discarded the medium, rinsed twice with PBS solution, and then the above mixture was added to the plate and cultured in a 37°C, 5% CO2 incubator for 6 hours. Then, a titer of 1×10 5 pfu / mL of vaccinia virus WR strain 100 μL infected cells, 37 ℃, 5% CO2 incubator culture for 2h. During the period, shake the 6-well plate every 15min to ensure the cell moist state. Subsequently, discard the culture medium, rinse twice with PBS solution, add 2mL of 1640 culture medium containing 2% FBS to each well, culture in a 37 ℃, 5% CO2 incubator for 48h, and observe the cell fluorescence expression with a fluorescence microscope. Collect the vaccinia virus-infected cells into EP tubes, freeze-thaw and lyse the cells 3 times at -80 ℃ and 37 ℃, and store the virus-containing cell lysate in a -80 ℃ refrigerator for later use.

[0049] Subsequently, the recombinant virus was blindly screened twice. Vero cells were inoculated in a 6-well plate. When the cells grew to 80%-90% the next day, the culture medium was discarded, washed twice with Hank's solution, 500 μl of the virus lysate produced in the above step was added, and the cells were cultured in a 37°C, 5% CO2 incubator for 2 hours, the supernatant was discarded, washed twice with Hank's solution, and gpt resistance screening solution was added to a final concentration of 1× in DMEM culture medium containing 2% FCS. The expression of Vero cell pathology was observed under a microscope, and the virus solution was collected after the cells were completely pathological. Repeat the above steps once.

[0050] Among them, the initial concentration of gpt resistance screening solution is: 10 mg / ml (670×) hypoxanthine, 10 mg / ml (40×) xanthine, and 10 mg / ml (400×) mycophenolic acid.

[0051] The virus solution obtained in the above steps was diluted 10 times in a gradient. Vero cells were inoculated into a 6-well plate, and when they grew to 80% the next day, the culture medium was discarded, and 500 μL of the above 10-fold gradient diluted virus solution was added to each well after rinsing twice with PBS solution, and cultured in a 37°C, 5% CO2 incubator for 2 hours. Then the supernatant was discarded, and after rinsing twice with PBS solution, 2 mL of DMEM culture medium containing 1×gpt resistance screening solution and 2% FBS was added to each well, and cultured in a 37°C, 5% CO2 incubator for 48 hours, and the fluorescence expression of Vero cells was observed under a fluorescence microscope. When typical plaques were formed, a single plaque expressing green fluorescence was picked up with a 1ml pipette tip and collected in a sterile EP tube containing 500 μL of serum-free DMEM culture medium, and the cells were repeatedly frozen and thawed 3 times at -80°C and 37°C, and stored in a -80°C refrigerator. Subsequently, each plaque infected a well separately, and the remaining steps were the same as above until the purified recombinant virus was obtained, named VV-Cas9-dmCZ.

[0052] Example 3: In vitro validation of recombinant vaccinia virus VV-Cas9-dmCZ

[0053] (1) Western Blot detection of Cas9 expression in recombinant virus fluid

[0054] Follow the instructions of the Flag-tagged kit of Boster Company, rinse the remaining glue on the surface of the splint and dry it, align and clamp the lower end to seal and put it into the splint rack, and make the glue according to the following formula: 10% separation gel: ddH2O 8ml, 30% acrylamide 6.7ml, 1.5M Tris pH8.8 5ml, 10% APS200μl, TEMED 10μl, add them to a 50ml centrifuge tube in sequence, mix them and immediately transfer them to a glass splint, add 1ml methanol solution to flatten the liquid surface; 5% concentrated gel: ddH2O 6.89ml, 30% acrylamide 1.7ml, 1M Tris pH6.8 1.25ml, 10% APS100μl, TEMED 10μl, add them to a 50ml centrifuge tube in sequence, mix them and immediately transfer them to a glass splint after discarding the methanol solution used to flatten the liquid surface. Use tweezers to remove all bubbles, insert a 1.5mm 10-hole comb, and wait for the concentrated gel to solidify. Rinse off the excess gel on the surface of the splint, put the glass splint on the electrophoresis rack, clamp the small plate inward and balance the other side with a balance plate, and pull out the comb. Use a syringe to clear the uncoagulated gel in the well, load the sample, 20μl per well, and 5μl marker. Run from 70V to 120V when it passes the interface between the concentrated gel and the separation gel and the marker separation band is obvious, and stop the power supply when the bromophenol blue band is about 1cm away from the bottom of the gel. Remove the gel plate from the rack and cut off the concentrated gel and unnecessary parts. Activate the 0.22nm membrane with methanol for 1 minute, rinse with deionized water for 1 minute, and then clamp the transfer device in the order of black + sponge + filter paper + glue + membrane + filter paper + sponge + white in the transfer, and power on black to black at 110V for 70 minutes, and power on in an ice bath. Block with 5% skim milk at 37℃ for 2h. Dilute the mouse anti-Flag tag antibody with 5 primary antibody diluent at a ratio of 1:1000 and incubate the blocked PVDF membrane on a shaker at 4℃ overnight. Wash with PBST 3-5 times, shake at room temperature for 8min each time. Dilute the goat anti-rabbit HRP enzyme-labeled secondary antibody with TBST 1:10000 and incubate on a shaker at room temperature for 1h. Wash three times with TBST, shake at room temperature for 10min each time. Mix 500μl of developer A and B, and develop.

[0055] The results showed that after the recombinant vaccinia virus infected the cells, the target protein Cas9 with the expected molecular weight was expressed. Figure 5 .

[0056] (2) Fluorescence microscopy to detect fluorescence attenuation

[0057] HeLa cells were inoculated into 6-well plates. The next day, the cells grew to 80% of the plate. The culture medium was discarded. After rinsing twice with PBS solution, 500 μl of purified VV-Cas9-dmCZ virus and VV-dcdk5 negative control virus were used to infect two wells of cells respectively. 500 μl of 1640 culture medium was added to the other two wells of cells as the control group. After 2 hours, the culture medium was discarded, and the plasmid LeGo-c-zeo expressing mCherry was transformed into the above cells respectively. After 6 hours, the supernatant was discarded, and each well was supplemented with 2 ml of 2% FBS 1640 culture medium. The cells were cultured in a 37°C, 5% CO2 incubator for 48 hours, and the cell fluorescence expression was observed with a fluorescence microscope.

[0058] The results showed that the fluorescence intensity of cells transfected with red fluorescent protein plasmids was significantly weakened compared with the control treated cells after VV-Cas9-dmCZ vaccinia virus infection of target cells ( Figure 7 ), proving that the CRISPR / Cas9 element delivered by the VV-Cas9-dmCZ vaccinia virus has cut the target gene in the cell, producing the expected gene editing effect.

[0059] (3) Flow cytometry detection of HeLa cell fluorescence reduction

[0060] HeLa cells were inoculated into 6-well plates. The next day, the cells grew to 80% of the cells. The culture medium was discarded. After rinsing twice with PBS solution, 500 μl of purified VV-Cas9-dmCZ virus and VV-dcdk5 negative control virus were used to infect two wells of cells respectively. 500 μl of 1640 culture medium was added to the other two wells of cells as the control group. After 2 hours, the culture medium was discarded, and the plasmid LeGo-c-zeo expressing mCherry was transformed into the above cells respectively. After 6 hours, the supernatant was discarded, and each well was supplemented with 2 ml of 2% FBS 1640 culture medium. The cells were cultured in a 37°C, 5% CO2 incubator for 48 hours. Then, the cells were collected in flow tubes respectively. After fixation with paraformaldehyde, flow cytometry analysis was performed to detect cell fluorescence.

[0061] result( Figure 8 )Similar to the above, VV-Cas9-dmCZ vaccinia virus infection of target cells caused their fluorescence intensity to decrease significantly, proving that the CRISPR / Cas9 element delivered by the VV-Cas9-dmCZ vaccinia virus has cut the target gene in the cell, producing the expected gene editing effect.

[0062] (4) Flow cytometry detection of 786-O cell fluorescence loss

[0063] 786-O cells stably transfected with mCherry gene were inoculated into 6-well plates. When they grew to 80% of the plate the next day, the culture medium was discarded. After rinsing twice with PBS solution, 500μl purified VV-Cas9-dmCZ virus and VV-dcdk5 negative control virus were used to infect two wells of cells respectively. 500μl DMEM culture medium was added to the other two wells of cells as the control group. After 2h, the culture medium was discarded, and 2ml 2% FBS DMEM culture medium was added to each well. The cells were cultured in a 37℃, 5% CO2 incubator for 48h, and the cell fluorescence expression was observed under a fluorescence microscope. The cells were then collected in flow tubes, fixed with paraformaldehyde, and flow cytometry was performed to detect cell fluorescence.

[0064] The results were similar to those above. VV-Cas9-dmCZ vaccinia virus infected target cells stably expressing red fluorescent protein, resulting in a significant decrease in the fluorescence intensity of the cells compared with the control-treated cells ( Fig. 9 ), proving that the CRISPR / Cas9 element delivered by the VV-Cas9-dmCZ vaccinia virus has cut the target gene in the cell, producing the expected gene editing effect.

[0065] (5) T7E1 enzyme detection of gene mutation

[0066] The VV-Cas9-dmCZ virus was used to infect 786-O cells stably transfected with mCherry, and the cell genomic DNA was extracted after 48 hours. Using mCherry-F / mCherry-Re as the primer pair and the cell genome as the template, a 500bp gene fragment near the target site was amplified. After gel excision and purification of the PCR product, hybridization was performed according to the following conditions: heating at 95°C for 5 minutes, cooling to 85°C at 2°C / s, cooling to 25°C at 0.1°C / s and maintaining for 5 minutes. The annealed PCR product was digested with T7E1 enzyme, and gel electrophoresis was performed, and the enzyme-cut bands were observed using a gel imager. The results showed the expected shearing band ( Fig.10 ).

[0067] (6) Sanger sequencing to detect gene mutations

[0068] In order to further analyze the insertion and deletion mutation sequence, the PCR product of the cleavage fragment generated after the above T7E1 enzyme treatment was TA cloned, and colonies were randomly picked for sequencing. The results showed gene mutation caused by shearing.

[0069] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the present invention.

Claims

1. A recombinant vaccinia virus expressing the CRISPR / Cas9 gene editing system, characterized in that: A CRISPR / Cas9 expression cassette is inserted into the TK gene region of the vaccinia virus; the recombinant vaccinia virus is constructed by transfecting Vero cells with the recombinant vaccinia virus expression plasmid pCB-Cas9-dmCZ, then infecting Vero cells with the wild-type vaccinia virus WR strain, and through an intracellular homologous recombination mechanism.

2. The recombinant vaccinia virus according to claim 1, characterized in that The complete nucleic acid sequence of the recombinant vaccinia vector expression plasmid pCB-Cas9-dmCZ is shown in SEQ ID No.

1.

3. The recombinant vaccinia virus according to claim 1, characterized in that The parent virus of the recombinant vaccinia virus is the vaccinia virus WR strain.

4. The recombinant vaccinia virus according to claim 1, characterized in that The structure of the recombinant vaccinia expression plasmid pCB-Cas9-dmCZ includes the Cas9 gene and its upstream artificially synthesized vaccinia virus early / late promoter P-se / l, gRNA and its upstream vaccinia virus modified H5 promoter mH5, and a selectable marker gene expression cassette in series with the target gene expression cassette; the P-se / l drives the expression of the Cas9 gene, and the mH5 drives the expression of the gRNA; wherein the gRNA is an RNA that guides the cutting of the mCherry red fluorescent protein marker gene, and the target gene is the Cas9 gene and the gRNA.

5. The recombinant vaccinia virus according to claim 4, characterized in that The nucleic acid sequence of the Cas9 gene is shown in SEQ ID No.3, the nucleic acid sequence of P-se / l is shown in SEQ ID No.4, the nucleic acid sequence of the gRNA is shown in SEQ ID No.2, and the nucleic acid sequence of mH5 is shown in SEQ ID No.

5.

6. The recombinant vaccinia virus according to claim 4, characterized in that The selectable marker genes include enhanced green fluorescent protein EGFP gene and gpt drug resistance gene.

7. The recombinant vaccinia virus according to claim 6, characterized in that The nucleic acid sequence of the selectable marker gene gpt drug resistance gene is shown as SEQ ID No.6, and the nucleic acid sequence of the selectable marker gene EGFP is shown as SEQ ID No.

7.

8. The recombinant vaccinia virus according to claim 6, characterized in that The EGFP gene is fused to the Cas9 gene via a 2A peptide, and the gpt drug resistance gene is driven for expression by the vaccinia virus P7.5 early / late promoter.

9. The recombinant vaccinia virus according to claim 6, characterized in that The amino acid sequence of the protein encoded by the Cas9 gene is shown in SEQ ID No.8; the amino acid sequence of the protein encoded by the selectable marker gene EGFP is shown in SEQ ID No.9; and the amino acid sequence of the protein encoded by the selectable marker gene gpt drug resistance gene is shown in SEQ ID No.

10.

10. Use of the recombinant vaccinia virus according to any one of claims 1 to 9 in targeted cell delivery and expression of the CRISPR / Cas9 system and gene editing of any endogenous or exogenous target gene in the target cell.